[{"id":"b6808cda-ab2a-4b3d-8cc3-0eab5b5b4415","acronym":"","url":"https://clinicaltrials.gov/study/NCT07157579","created_at":"2025-09-06T13:39:27.500Z","updated_at":"2025-09-06T13:39:27.500Z","phase":"","brief_title":"Notch 1 Mutation in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patient","source_id_and_acronym":"NCT07157579","lead_sponsor":"Sohag University","biomarkers":" BCL2 • NOTCH1","pipe":"","alterations":" ","tags":["BCL2 • NOTCH1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-09-05"},{"id":"6496b67a-0445-408d-84b5-b4ec4d9b149e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06846463","created_at":"2025-03-03T10:04:54.767Z","updated_at":"2025-03-03T10:04:54.767Z","phase":"Phase 2","brief_title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","source_id_and_acronym":"NCT06846463","lead_sponsor":"Virginia Commonwealth University","biomarkers":" BCL2 • NOTCH1 • MYD88 • CD79B • CD5","pipe":"","alterations":" ","tags":["BCL2 • NOTCH1 • MYD88 • CD79B • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/31/2029","primary_completion_date":" 07/31/2029","study_txt":" Completion: 07/31/2032","study_completion_date":" 07/31/2032","last_update_posted":"2025-02-26"},{"id":"7c08cf87-45ad-4ad1-a2a0-cd9cc9ee571c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05203601","created_at":"2023-12-27T20:17:30.683Z","updated_at":"2024-07-02T16:35:25.088Z","phase":"Phase 1","brief_title":"A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.","source_id_and_acronym":"NCT05203601","lead_sponsor":"Shanghai Institute Of Biological Products","biomarkers":" EGFR • HER-2 • TP53 • PIK3CA • ERBB3 • NOTCH1 • NRG1 • NOTCH2 • FAT1 • NOTCH4","pipe":" | ","alterations":" HER-2 overexpression","tags":["EGFR • HER-2 • TP53 • PIK3CA • ERBB3 • NOTCH1 • NRG1 • NOTCH2 • FAT1 • NOTCH4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-12-27"},{"id":"a20d813c-0be4-46f6-9eac-b9a7b8cfecb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05187767","created_at":"2022-01-12T15:53:45.698Z","updated_at":"2024-07-02T16:36:00.723Z","phase":"","brief_title":"Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs","source_id_and_acronym":"NCT05187767","lead_sponsor":"University of Roma La Sapienza","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-11-08"},{"id":"f70ef90a-fdc9-405b-b396-50a810ed6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273099","created_at":"2022-03-10T14:58:06.191Z","updated_at":"2024-07-02T16:36:13.173Z","phase":"","brief_title":"Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma","source_id_and_acronym":"NCT05273099","lead_sponsor":"Università degli Studi di Ferrara","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A","pipe":" | ","alterations":" JAK3 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-12"},{"id":"46cca4fa-b3b4-4bb3-bcc4-83de6f20a7cd","acronym":"GLIONOTCH","url":"https://clinicaltrials.gov/study/NCT04809597","created_at":"2021-03-22T11:52:18.415Z","updated_at":"2024-07-02T16:36:33.019Z","phase":"","brief_title":"Does Notch Regulate Glioma Proliferation ?","source_id_and_acronym":"NCT04809597 - GLIONOTCH","lead_sponsor":"University Hospital, Montpellier","biomarkers":" NOTCH1 • SNAI2","pipe":"","alterations":" ","tags":["NOTCH1 • SNAI2"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/20/2021","study_completion_date":" 01/20/2021","last_update_posted":"2021-03-22"},{"id":"aba33b26-ab98-41c3-96d4-aace62ea6c54","acronym":"","url":"https://clinicaltrials.gov/study/NCT00899366","created_at":"2021-01-18T03:27:26.248Z","updated_at":"2024-07-02T16:36:50.448Z","phase":"","brief_title":"DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00899366","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" NOTCH1","pipe":" | ","alterations":" NOTCH1 mutation","tags":["NOTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 12/28/2006","start_date":" 12/28/2006","primary_txt":" Primary completion: 07/30/2009","primary_completion_date":" 07/30/2009","study_txt":" Completion: 07/30/2009","study_completion_date":" 07/30/2009","last_update_posted":"2020-02-05"},{"id":"694aae4f-2bb5-4c6d-9fbf-8b38da8c30f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01013597","created_at":"2021-01-18T03:58:23.715Z","updated_at":"2025-02-25T15:50:36.160Z","phase":"Phase 2","brief_title":"Trial of LBH589 in Metastatic Thyroid Cancer","source_id_and_acronym":"NCT01013597","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" NOTCH1","pipe":" | ","alterations":" NOTCH1 expression","tags":["NOTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Farydak (panobinostat)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2019-11-29"},{"id":"d908dcee-ca16-4789-86c9-2c8568713d62","acronym":"","url":"https://clinicaltrials.gov/study/NCT01476592","created_at":"2021-01-18T06:09:40.287Z","updated_at":"2024-07-02T16:36:53.528Z","phase":"","brief_title":"A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors","source_id_and_acronym":"NCT01476592","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" NOTCH1 • HES1","pipe":" | ","alterations":" NOTCH1 expression","tags":["NOTCH1 • HES1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH1 expression"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 10/11/2018","study_completion_date":" 10/11/2018","last_update_posted":"2019-11-18"},{"id":"80dea25b-d9ea-4ed6-b053-ee4a0189b047","acronym":"","url":"https://clinicaltrials.gov/study/NCT00878189","created_at":"2021-01-18T03:21:27.001Z","updated_at":"2024-07-02T16:36:53.866Z","phase":"Phase 1","brief_title":"A Trial In Patients With Advanced Cancer And Leukemia","source_id_and_acronym":"NCT00878189","lead_sponsor":"Pfizer","biomarkers":" NOTCH1 • NICD • HES4","pipe":" | ","alterations":" NOTCH1 expression","tags":["NOTCH1 • NICD • HES4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ogsiveo (nirogacestat)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 06/25/2009","start_date":" 06/25/2009","primary_txt":" Primary completion: 01/10/2013","primary_completion_date":" 01/10/2013","study_txt":" Completion: 11/22/2016","study_completion_date":" 11/22/2016","last_update_posted":"2019-11-12"},{"id":"ffc3eeaf-0c0b-4248-ac40-a4e3ffc99220","acronym":"","url":"https://clinicaltrials.gov/study/NCT02518113","created_at":"2021-01-18T12:10:07.428Z","updated_at":"2024-07-02T16:36:55.784Z","phase":"Phase 1b","brief_title":"A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL","source_id_and_acronym":"NCT02518113","lead_sponsor":"Eli Lilly and Company","biomarkers":" NOTCH1 • FBXW7","pipe":" | ","alterations":" FBXW7 mutation • NOTCH mutation","tags":["NOTCH1 • FBXW7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FBXW7 mutation • NOTCH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • crenigacestat (LY3039478)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 01/15/2018","primary_completion_date":" 01/15/2018","study_txt":" Completion: 01/15/2018","study_completion_date":" 01/15/2018","last_update_posted":"2019-09-11"}]